QVAR 40 (beclomethasone dipropionate) by Teva is anti-inflammatory activity. First approved in 2000.
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
QVAR 40 is a metered-dose inhaled corticosteroid containing beclomethasone dipropionate, used to treat asthma by reducing airway inflammation. The drug works as a prodrug that rapidly converts to its active form (17-BMP), which binds the glucocorticoid receptor with high affinity to inhibit inflammatory cells and mediators. It provides a favorable ratio of topical anti-inflammatory activity to systemic effects at recommended doses.
Product is in peak revenue stage with stable, mature market position; teams are typically focused on optimization and cost management rather than growth expansion.
anti-inflammatory activity. The precise mechanism of corticosteroid action on asthma is not known. Corticosteroids have been shown to have multiple anti-inflammatory effects, inhibiting both inflammatory cells (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®
Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INH
Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)
Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma
Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)
Worked on QVAR 40 at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~5 years — strategic planning for patent cliff underway
Working on QVAR 40 offers career opportunities in commercial optimization, market access strategy, and competitive defense in a stable, established respiratory market. The product's mature lifecycle favors professionals skilled in managed care negotiations, value demonstration, and customer retention rather than new market development.